Tags

Type your tag names separated by a space and hit enter

[Therapeutic options in idiopathic chronic urticaria].
Rev Alerg Mex. 2005 Mar-Apr; 52(2):77-82.RA

Abstract

BACKGROUND

Chronic idiopathic urticaria is a clinic entity that is manifested by wheals of more than six weeks of evolution, without identification of the causing agent, and sometimes resistant to conventional treatment. There are improvements with leukotriene receptor antagonists.

OBJECTIVE

To evaluate the clinical efficacy of montelukast and desloratadine individually and combined, compared with hydroxicine.

PATIENTS AND METHODS

The trial included 40 subjects with chronic idiopathic urticaria referred from the outpatient allergy service. They were randomly divided into four groups to receive: hydoxicine, montelukast, montelukast plus desloratadine, and desloratadine alone during six weeks. The assessments compared the first and sixth weeks.

RESULTS

All therapeutic options are effective, with statistical significance, highlighting that the new therapeutic modes are safe and have better resolution of lesions and symptoms.

CONCLUSIONS

All the alternatives are viable, considering they are adjusted to each patient, adverse symptoms, socio-economic status and clinical severity.

Authors+Show Affiliations

Servicio de alergia e inmunología clinica, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, IMSS.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

spa

PubMed ID

16158780

Citation

Mora, Patricia Montero, et al. "[Therapeutic Options in Idiopathic Chronic Urticaria]." Revista Alergia Mexico (Tecamachalco, Puebla, Mexico : 1993), vol. 52, no. 2, 2005, pp. 77-82.
Mora PM, González Pérez Mdel C, Jiménez Villarruel M, et al. [Therapeutic options in idiopathic chronic urticaria]. Rev Alerg Mex. 2005;52(2):77-82.
Mora, P. M., González Pérez, M. d. e. l. . C., Jiménez Villarruel, M., Rodriguez Castro, E., & Fogelbach, G. G. (2005). [Therapeutic options in idiopathic chronic urticaria]. Revista Alergia Mexico (Tecamachalco, Puebla, Mexico : 1993), 52(2), 77-82.
Mora PM, et al. [Therapeutic Options in Idiopathic Chronic Urticaria]. Rev Alerg Mex. 2005 Mar-Apr;52(2):77-82. PubMed PMID: 16158780.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Therapeutic options in idiopathic chronic urticaria]. AU - Mora,Patricia Montero, AU - González Pérez,Maria del Carmen, AU - Jiménez Villarruel,Margarita, AU - Rodriguez Castro,Eduardo, AU - Fogelbach,Guillermo Guidos, PY - 2005/9/15/pubmed PY - 2005/10/27/medline PY - 2005/9/15/entrez SP - 77 EP - 82 JF - Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) JO - Rev Alerg Mex VL - 52 IS - 2 N2 - BACKGROUND: Chronic idiopathic urticaria is a clinic entity that is manifested by wheals of more than six weeks of evolution, without identification of the causing agent, and sometimes resistant to conventional treatment. There are improvements with leukotriene receptor antagonists. OBJECTIVE: To evaluate the clinical efficacy of montelukast and desloratadine individually and combined, compared with hydroxicine. PATIENTS AND METHODS: The trial included 40 subjects with chronic idiopathic urticaria referred from the outpatient allergy service. They were randomly divided into four groups to receive: hydoxicine, montelukast, montelukast plus desloratadine, and desloratadine alone during six weeks. The assessments compared the first and sixth weeks. RESULTS: All therapeutic options are effective, with statistical significance, highlighting that the new therapeutic modes are safe and have better resolution of lesions and symptoms. CONCLUSIONS: All the alternatives are viable, considering they are adjusted to each patient, adverse symptoms, socio-economic status and clinical severity. SN - 0002-5151 UR - https://www.unboundmedicine.com/medline/citation/16158780/[Therapeutic_options_in_idiopathic_chronic_urticaria]_ L2 - https://medlineplus.gov/hives.html DB - PRIME DP - Unbound Medicine ER -